Claudia Piccinini

Dr. Claudia Piccinini

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
CPClaudia Piccinini
Claudia Piccinini
SCSilvia Carloni
Silvia Carloni
CAChiara Arienti
Chiara Arienti
EPElena Pancisi
Elena Pancisi
Francesca FaniniFrancesca Fanini
Francesca Fanini
Massimiliano PetriniMassimiliano Petrini
Massimiliano Petrini
For advanced therapy medicinal products, the development and validation of potency assays are required, in accordance with international guidelines, to characterise the product and obtain reliable and consistent data. Our purpose was to validate the killing assay for the evaluation of autologous anti-CD19 chimeric antigen receptor (CAR) T potency. We used CD4 + and CD8 + lymphocytes or anti-CD19 CAR-T cells as effector cells and REH (CD19 +) or MOLM-13 (CD19 −) cell lines as target cells. After co-culturing target and effector cells (1:1 ratio) for 24 h, samples were labelled with 7-AAD, anti-CD3 and anti-CD19 antibodies and the frequency of CD19 + dead cells was evaluated by flow cytometry. In order to verify the CAR-T specificity for the CD19 + target, the co-culture between CAR-T and REH or MOLM-13 at different effector-to-target ratios was scheduled. Moreover, not transduced CD4 + and CD8 + lymphocytes were tested in comparison with CAR-T from the same donor to demonstrate the assay specificity. Linearity and accuracy were evaluated, and established acceptance criteria were compiled for both parameters (r2 ≥ 0.97 for linearity and average relative error ≤ 10% for accuracy). Furthermore, the method was considered robust when performed between 23 and 25 h of co-culture, and the intra-assay, inter-assay and inter-day precision was obtained. Finally, in order to verify the inter-analyst precision, the test was executed by three different operators and the intra-class correlation coefficient was > 0.4 in both cases. In conclusion, we consider this CAR-T potency assay as validated and usable in all steps of product development and quality control.

23 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
EPElena Pancisi
Elena Pancisi
AGAnna Maria Granato
Anna Maria Granato
ESEmanuela Scarpi
Emanuela Scarpi
laura ridolfilaura ridolfi
laura ridolfi
SCSilvia Carloni
Silvia Carloni
Massimiliano PetriniMassimiliano Petrini
Massimiliano Petrini
Advanced therapy medical products (ATMPs) are rapidly growing as innovative medicines for the treatment of several diseases. Hence, the role of quality analytical tests to ensure consistent product safety and quality has become highly relevant. Several clinical trials involving dendritic cell (DC)-based vaccines for cancer treatment are ongoing at our institute. The DC-based vaccine is prepared via CD14+ monocyte differentiation. A fresh dose of 10 million DCs is administered to the patient, while the remaining DCs are aliquoted, frozen, and stored in nitrogen vapor for subsequent treatment doses. To evaluate the maintenance of quality parameters and to establish a shelf life of frozen vaccine aliquots, a stability program was developed. Several parameters of the DC final product at 0, 6, 12, 18, and 24 months were evaluated. Our results reveal that after 24 months of storage in nitrogen vapor, the cell viability is in a range between 82% and 99%, the expression of maturation markers remains inside the criteria for batch release, the sterility tests are compliant, and the cell costimulatory capacity unchanged. Thus, the data collected demonstrate that freezing and thawing do not perturb the DC vaccine product maintaining over time its functional and quality characteristics.

18 April 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JBJenny Bulgarelli
Jenny Bulgarelli
CPClaudia Piccinini
Claudia Piccinini
ESEmanuela Scarpi
Emanuela Scarpi
GGGiorgia Gentili
Giorgia Gentili
LRLaura Renzi
Laura Renzi
LRLaura Ridolfi
Laura Ridolfi
Background: Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a central role in the immune system, orchestrating immune response against tumors. We previously demonstrated that DC-based vaccination effectively induces anti-tumor immunity, yet at the same time showing a robust safety profile, making this treatment a potential candidate for effective adjuvant immunotherapy. To explore this possibility, we designed a randomized phase II trial (EudraCT no. 2014-005123-27) to provide a complementary autologous DC vaccination to patients (pts) with resected stage III/IV melanoma. Methods: Overall, a total of 18 eligible pts were included in this study, 10 of whom received 6 monthly DC vaccination cycles combined with IL-2 administration (arm A), and 8 pts were enrolled in the follow-up observational cohort (arm B). A deep immune biomarkers profiling by multiplex immunoassay, human leukocyte antigens (HLA) typing, multiparametric flow cytometry and in situ tumor microenvironment analysis was performed for the entire pts cohort. The immunological response was assessed in vivo by DTH test and ex vivo against selected melanoma-associated antigens applying the IFN-γ ELISPOT assay. Results: Pts receiving DC vaccination showed a better relapse-free survival compared to the observational cohort (median 6.6 months, 95% CI, 2.3–not reached (nr) (arm A) vs 5.2 months, 95% CI, 2.5–nr (arm B), not significant), with a favorable trends for female pts (median 15.5 months, 95% CI, 2.6–nr (female) vs 3.3, 95% CI, 2.3–nr (male)), pts with less than 60 years (median 22.5 months, 95% CI, 2.6–nr (age < 60) vs 4.7 months, 95% CI, 2.3–nr (age ≥ 60), and pts with wild-type BRAF status (median 22.5 months, 95% CI, 8.6–nr (BRAF wt) vs 3.8 months, 95% CI, 2.3–nr (BRAF mutated). The toxicity profile was favourable, with no severe adverse events and only mild, manageable reactions. Moreover, additional immune response data suggested increased immune modulation in vaccinated patients, which may reflect a shift in immune dynamics. Conclusions: Our findings support the safety and tolerability of DC vaccination as an adjuvant treatment for melanoma, demonstrating significant immune modulation at both the tumor site and peripherally in relapsed and non-relapsed patients. These results highlight the potential of autologous, personalised DC-based therapies and pave the way for the development of innovative immunotherapy combinations in future treatment strategies. Trial registration ClinicalTrials.gov NCT02718391; EudraCT no. 2014-005123-27.

8 July 2024 in Cytotherapy
Verified
Journal Article
Open access
AGAnna Maria Granato
Anna Maria Granato
EPElena Pancisi
Elena Pancisi
CPClaudia Piccinini
Claudia Piccinini
MSMonica Stefanelli
Monica Stefanelli
SPSara Pignatta
Sara Pignatta
Massimiliano PetriniMassimiliano Petrini
Massimiliano Petrini
Dendritic cells (DCs) are professional antigen-presenting cells of the mammalian immune system. Ex vivo differentiated DCs represent a unique Advanced Therapy Medicinal Product (ATMP), used in several clinical trials as personalized cancer immunotherapy. The therapy's reliability depends on its capacity to produce high-quality mature DCs (mDCs) in compliance with Good Manufacturing Practices. From March 2010 to December 2023, 103 patients were enrolled in multiple clinical trials at the Immuno-Gene Therapy Factory at IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori". Six hundred forty-two doses were produced, and the manufacturing process was implemented to optimize production. Our study is a retrospective analysis focusing on the quality control results. We retrospectively analyzed the results of the quality control tests carried out on each produced batch, evaluating viability, purity and phenotype of mDCs and their quality in terms of microbiological safety. The data obtained are given with median and interquartile range. The batches were found to be microbiologically safe in terms of sterility, mycoplasma, and endotoxins. An increase in DC maturation markers was found. The release criteria checks showed a high percentage of viability and purity was maintained during the production process. Our findings have confirmed that the measures implemented have ensured the safety of the products and have contributed to the establishing a robust "Pharmaceutical Quality System." This has enabled many safe mDCs to be produced for clinical trials.

Verified
Journal Article
Open access
PDF file
SCSilvia Carloni
Silvia Carloni
CPClaudia Piccinini
Claudia Piccinini
EPElena Pancisi
Elena Pancisi
VSValentina Soldati
Valentina Soldati
MSMonica Stefanelli
Monica Stefanelli
Massimiliano PetriniMassimiliano Petrini
Massimiliano Petrini
For many years, oncological clinical trials have taken advantage of dendritic cells (DC) for the design of DC-based cellular therapies. This has required the design of suitable quality control assays to evaluate the potency of these products. The purpose of our work was to develop and validate a novel bioassay that uses flow cytometry as a read-out measurement. In this method, CD3+ cells are labeled with a fluorescent dye and the DC costimulatory activity is measured by the degree of T cell proliferation caused by the DC–T cell interaction. The validation of the method was achieved by the evaluation of essential analytical parameters defined by international guidelines. Our results demonstrated that the method could be considered specific, selective, and robust. The comparison between measured values and estimated true values confirmed a high level of accuracy and a lack of systematic error. Repeated experiments have shown the reproducibility of the assay and the proportionality between the potency and the DC amount has proven its linearity. Our results suggest that the method is compliant with the guidelines and could be adopted as a quality control assay or batch-release testing within GMP facilities.

20 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SCSilvia Carloni
Silvia Carloni
CPClaudia Piccinini
Claudia Piccinini
CAChiara Arienti
Chiara Arienti
DLDario Armando Leone
Dario Armando Leone
EPElena Pancisi
Elena Pancisi
MPMassimiliano Petrini
Massimiliano Petrini
Introduction: Robust quality control methods are required to ensure the safety, efficacy and consistency of advanced therapy medicinal products. Potency assays play a critical role in evaluating their biological activity. While ELISpot remains the reference method for single-cell cytokine analysis, it has several limitations such as a lack of standardisation and limited capacity for multiparametric characterisation. This study aimed to develop and validate a flow cytometry-based potency assay for the assessment of single-cell IFN-γ secretion. Methods: The commercially available Miltenyi Biotec IFN-γ Secretion Assay - Detection Kit, based on flow cytometry, was modified to assess the potency of dendritic cell-based vaccines. To ensure its reliability, our assay was rigorously evaluated for specificity, linearity, accuracy, robustness and precision. Comparative analysis with the ELISpot assay was also performed to assess agreement between the two methods. Results: Method development resulted in reduced sample requirements and optimisation of cytokine secretion conditions to generate a response to antigen-presenting cell stimulus. Validation showed that the specificity, linearity, accuracy, robustness and precision consistently met the acceptance criteria. Comparative analysis with ELISpot demonstrated high correlation and agreement, with no evidence of systematic or proportional error. Discussion: The developed assay provides a reliable, scalable and efficient flow cytometry-based approach for cytokine secretion analysis and represents an alternative method to ELISpot. Its advantages in sensitivity, efficiency and cost effectiveness make it a valuable tool for advanced therapy quality control and immune monitoring in clinical research. The flow cytometry further enhances its potential by enabling multiparametric immune profiling, supporting comprehensive characterisation of cellular products in both preclinical and clinical applications.